Safe long-term therapy of Cushing's syndrome over 37 years with mitotane

Front Endocrinol (Lausanne). 2024 Feb 19:15:1294415. doi: 10.3389/fendo.2024.1294415. eCollection 2024.

Abstract

While suggested, surgery is not always possible as a first-line treatment of Cushing's Disease (CD). In such cases, patients require medical therapy in order to prevent complications resulting from hypercortisolism. Although there has been a wide expansion in pharmacological options in recent years, mitotane was the agent of choice for treating hypercortisolism decades ago. Due to the introduction of other therapies, long-term experience with mitotane remains limited. Here, we report the case of a woman with CD who was treated with mitotane for 37 years. During the treatment period, biochemical and clinical disease control was achieved and the patient had two uncomplicated pregnancies. Drug-related side effects remained moderate and could be controlled by several dose adjustments. Our case highlights the ability of mitotane to allow an effective control of hypercortisolism and to represent a safe treatment option in special situations where CD requires an alternative therapeutic approach. Furthermore, we provide a literature review of the long-term use of mitotane and reported cases of pregnancy in the context of mitotane therapy.

Keywords: Cushing’s syndrome; adrenostatic drug; long-term treatment; mitotane; pregnancy.

Publication types

  • Case Reports
  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cushing Syndrome* / drug therapy
  • Drug-Related Side Effects and Adverse Reactions*
  • Female
  • Humans
  • Mitotane / therapeutic use
  • Pituitary ACTH Hypersecretion*
  • Pregnancy

Substances

  • Mitotane

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The authors acknowledge support from the German Research Foundation (DFG) and Universität Leipzig within the program of Open Access Publishing.